Lyme Disease Vaccine Sales

Lyme Disease Vaccine Sales Market Outlook

The global Lyme disease vaccine market is projected to reach approximately USD 1.2 billion by 2035, exhibiting a compound annual growth rate (CAGR) of around 7.5% during the forecast period from 2025 to 2035. This growth is primarily driven by the increasing prevalence of Lyme disease, heightened awareness among the public regarding tick-borne illnesses, and advancements in vaccine technology. As more individuals become aware of the risks associated with Lyme disease, there is a greater demand for effective vaccination options. Additionally, research and development initiatives by various pharmaceutical companies have led to the introduction of innovative vaccines, further contributing to market growth. The ongoing efforts to develop effective vaccines that can provide long-term immunity against Lyme disease are also pivotal in shaping the future landscape of this market.

Growth Factor of the Market

Several factors are propelling the growth of the Lyme disease vaccine market. Firstly, the rising incidence of Lyme disease, particularly in areas where ticks are prevalent, has led to an increased demand for vaccines as a preventive measure. Public health campaigns and increased education regarding the importance of vaccination in combatting tick-borne diseases have also been influential. Moreover, advancements in biotechnology and vaccine development methodologies are facilitating the emergence of more effective and safer vaccine options. In addition, government initiatives aimed at controlling and preventing tick-borne diseases are encouraging vaccine research and development, thus fueling market growth. Finally, the integration of digital health solutions for better health monitoring and awareness is paving the way for improved access to vaccinations, further driving market demand.

Key Highlights of the Market

• Steady growth in market value, with a projected CAGR of 7.5% from 2025 to 2035.
• Increased awareness and education regarding Lyme disease and its prevention through vaccination.
• Advancements in vaccine technology leading to the development of innovative vaccine types.
• Government support and initiatives to combat tick-borne diseases through vaccination programs.
• A rising number of research and development collaborations among pharmaceutical companies.

By Product Type

Recombinant Protein Vaccines:

Recombinant protein vaccines represent a significant segment within the Lyme disease vaccine market. These vaccines utilize genetically engineered proteins derived from the Lyme disease-causing bacteria, which stimulate an immune response without causing the disease itself. This segment has gained traction due to its ability to produce a strong and specific immune response, making it an effective preventive measure. The increasing focus on safety and efficacy in vaccine development has resulted in a preference for recombinant technology, further propelling the growth of this segment. With ongoing clinical trials and research targeting the refinement of these vaccines, recombinant protein vaccines are expected to play a crucial role in the future of Lyme disease prevention.

Whole Cell Vaccines:

Whole cell vaccines are another important type within the Lyme disease vaccine market. These vaccines utilize killed or inactivated forms of the Lyme bacteria to elicit an immune response. While whole cell vaccines have historically been effective, they have faced challenges related to safety and side effects. However, advancements in vaccine formulation and delivery methods are helping to mitigate these concerns. The market for whole cell vaccines is expected to grow as public health initiatives focus on comprehensive vaccination strategies to prevent Lyme disease. These vaccines can be particularly beneficial in endemic regions where tick populations are high, providing a robust option for community-wide vaccination programs.

DNA Vaccines:

DNA vaccines represent a novel approach within the Lyme disease vaccine landscape, characterized by their ability to use a small, circular piece of DNA that encodes antigens from the Lyme bacteria. This type of vaccine can induce both humoral and cellular immune responses, presenting a dual mode of action against the disease. The potential for ease of production and long-term immunity makes DNA vaccines an exciting area of research and development. Although still in the experimental stage for Lyme disease, advancements in genetic engineering and vaccine delivery systems are paving the way for future applications. As the technology matures, DNA vaccines could emerge as a transformative solution in preventing Lyme disease.

Live Attenuated Vaccines:

Live attenuated vaccines are developed using weakened forms of the pathogen that cause Lyme disease. These vaccines provide an effective means of eliciting a strong immune response, resulting in long-lasting immunity. However, safety concerns associated with the potential for reversion to virulence have slowed their development and acceptance in some areas. Despite these challenges, ongoing research into improving safety profiles and delivery methods is reigniting interest in live attenuated vaccines. If successful, these vaccines could complement existing preventive strategies against Lyme disease, particularly in high-risk populations.

Subunit Vaccines:

Subunit vaccines, which contain only specific antigenic components of the Lyme bacteria, are another important category in the vaccine market. By using only the essential parts of the pathogen that provoke an immune response, subunit vaccines tend to have a favorable safety profile compared to their whole-cell counterparts. This segment is gaining momentum as it aligns with the growing demand for targeted and effective vaccination strategies. Research efforts aimed at identifying the most effective subunit components are ongoing, and as these vaccines move through the clinical phases, they may become a key player in the Lyme disease vaccination landscape.

By Application

Hospitals:

Hospitals play a crucial role as a primary application segment for Lyme disease vaccines. Within hospital settings, vaccination programs can be implemented to target high-risk populations, such as individuals exposed to ticks due to outdoor activities, or healthcare workers involved in treating Lyme disease cases. Hospitals are also pivotal in educating patients about the risks associated with Lyme disease and the importance of vaccination. As health systems increasingly focus on preventive care, the role of hospitals in administering Lyme disease vaccines is expected to expand, subsequently contributing to the overall growth of the market.

Clinics:

Clinics, particularly those specializing in infectious diseases or public health, are essential points of vaccination for Lyme disease. These facilities often provide immunization services to patients, emphasizing the importance of preventive healthcare measures. The accessibility of clinics allows for more widespread distribution of vaccines, ensuring that individuals at risk of Lyme disease receive timely vaccinations. Moreover, clinics serve as critical venues for educating patients about ticks, Lyme disease symptoms, and the benefits of vaccination, which can further enhance community health outcomes. As a result, clinics are expected to play a significant role in advancing Lyme disease vaccination efforts.

Retail Pharmacies:

Retail pharmacies are increasingly emerging as important distribution channels for Lyme disease vaccines. With their widespread availability and accessibility, retail pharmacies provide convenient options for individuals seeking vaccinations. Many pharmacies are expanding their services to include immunization programs, making it easier for consumers to receive necessary vaccines without the need for a formal medical appointment. This trend is fueled by the growing recognition of the role pharmacists can play in public health initiatives. The partnership between retail pharmacies and healthcare providers is likely to enhance vaccine accessibility, thereby contributing to the growth of the Lyme disease vaccine market.

E-Commerce:

The e-commerce segment is becoming increasingly relevant in the Lyme disease vaccine market. As consumers increasingly turn to online platforms for healthcare products and services, the potential for e-commerce to facilitate vaccine distribution is significant. Online sales enable individuals to access information on Lyme disease vaccines, read reviews, and compare options before making a decision. Additionally, e-commerce platforms can provide education on Lyme disease prevention, leading to enhanced awareness and demand for vaccination. Although regulatory challenges exist in the online sale of vaccines, progress in telehealth and digital health solutions suggests that e-commerce will continue to play a critical role in the distribution of Lyme disease vaccines.

By Distribution Channel

Online Sales:

Online sales have emerged as a vital distribution channel for Lyme disease vaccines, especially in the wake of the COVID-19 pandemic, which accelerated the adoption of digital solutions in healthcare. This channel allows individuals to access vaccines conveniently and discreetly, reducing barriers to vaccination. Through telehealth consultations, patients can receive personalized recommendations and schedule vaccinations through various online platforms. As the healthcare landscape evolves, the online sales channel is expected to grow in prominence, particularly for preventive health products like vaccines, providing an accessible means for individuals at risk of Lyme disease to receive immunization.

Retail Sales:

Retail sales remain a fundamental distribution channel for Lyme disease vaccines, allowing for immediate access within community settings. Pharmacies, grocery stores, and other retail outlets are increasingly offering vaccination services, which enhances convenience for customers and encourages proactive health management. Retail sales cater to patients who may not have easy access to healthcare facilities or prefer the convenience of receiving vaccines during routine shopping trips. This direct access fosters increased vaccination uptake among the general population and is essential for reaching individuals in endemic areas, thereby contributing to the overall efforts to control Lyme disease.

By Ingredient Type

Outer surface protein A (OspA):

Outer surface protein A (OspA) is a significant ingredient in Lyme disease vaccines due to its role as a protective antigen. Vaccines utilizing OspA have demonstrated the ability to stimulate immune responses that can neutralize the Lyme bacteria effectively. This ingredient has been a focal point in the development of several vaccine candidates, as its specific targeting can enhance the immune response and offer long-term protection. The ongoing research into the optimization of OspA-based vaccines continues to be a key driver in advancing Lyme disease vaccine technology and improving vaccine efficacy.

Outer surface protein C (OspC):

Outer surface protein C (OspC) is another critical component utilized in Lyme disease vaccines. OspC plays a key role in the bacteria's ability to evade the host's immune system, making it an essential target for vaccine development. By incorporating OspC into vaccine formulations, developers aim to elicit a robust immune response that effectively recognizes and responds to the virus. The focus on OspC is indicative of the ongoing efforts to enhance vaccine effectiveness in preventing Lyme disease, with research highlighting its potential for eliciting strong protective responses.

VlsE:

VlsE is a vital antigen included in the formulation of Lyme disease vaccines, known for its ability to undergo antigenic variation. This property allows the bacteria to evade the host immune response, making VlsE a strategic target for vaccine development. By including VlsE in the vaccine composition, developers aim to stimulate a comprehensive immune response capable of recognizing and combating various strains of the Lyme bacteria. The incorporation of VlsE into vaccine formulations reflects the ongoing advancements in vaccine research that prioritize the long-term efficacy of Lyme disease prevention strategies.

DbpA:

DbpA is another significant ingredient in the landscape of Lyme disease vaccines. DbpA, known for its role in the adherence of the bacteria to tick and mammalian hosts, serves as an important target for immune responses. Vaccines that utilize DbpA as an antigen aim to disrupt the bacterial colonization process, thereby preventing infection. The strategic incorporation of DbpA into vaccine formulations is indicative of the innovative approaches being taken to enhance vaccine efficacy and broaden the scope of protection against Lyme disease.

DbpB:

DbpB complements the role of DbpA in vaccine development and is recognized for contributing to the adherence and invasion processes of the Lyme bacteria. By targeting DbpB, vaccine formulations can potentially strengthen the immune response and improve the effectiveness of Lyme disease vaccines. The focus on utilizing multiple antigens, including DbpB, highlights the evolving strategies in vaccine research aimed at providing robust protection against the complexities of Lyme disease. As research advances, the incorporation of DbpB into vaccine candidates is expected to enhance their overall effectiveness and applicability.

By Outer Surface Protein A

OspA-based Vaccines:

OspA-based vaccines have gained attention in the Lyme disease vaccine market due to their ability to elicit robust immune responses against the Lyme bacteria. These vaccines leverage the outer surface protein A, which is highly immunogenic and plays a critical role in the bacteria's lifecycle. Research indicates that OspA-based vaccines can provide effective protection against Lyme disease by stimulating the immune system to recognize and attack the bacteria upon exposure. As vaccine developers focus on increasing the efficacy and safety of OspA-based formulations, their potential market share is expected to grow, particularly among populations at higher risk of Lyme disease exposure.

By Outer Surface Protein C

OspC-based Vaccines:

OspC-based vaccines are another promising segment in the Lyme disease vaccine market, utilizing the outer surface protein C as a key immunogenic target. OspC plays a vital role in the ability of the Lyme bacteria to adapt and evade the host immune response, making it a strategic focus for vaccine development. By eliciting targeted immune responses against OspC, these vaccines aim to provide effective protection against various Lyme disease strains. The continued focus on OspC in vaccine research underscores its importance in advancing the overall efficacy of Lyme disease prevention strategies and enhancing public health initiatives.

By Region

The geographical distribution of the Lyme disease vaccine market reveals significant trends and variations in uptake and awareness across different regions. North America, particularly the United States, is presently the largest market for Lyme disease vaccines, reflecting the high incidence rates of Lyme disease and increased public health initiatives aimed at prevention. The region is expected to witness a CAGR of 8.0% over the forecast period as awareness campaigns and vaccination programs become more widespread. In contrast, Europe is also experiencing growth in the Lyme disease vaccine market due to rising awareness and the establishment of more robust healthcare infrastructure targeting tick-borne diseases. The European market is expected to grow at a CAGR of around 6.5%, driven by similar factors such as public education and vaccination initiatives.

In the Asia Pacific region, the Lyme disease vaccine market is gradually gaining traction, albeit from a smaller base compared to North America and Europe. The increasing urbanization and environmental changes resulting in tick habitat expansion are contributing to a heightened risk of Lyme disease, prompting governmental and health organizations to consider preventive measures such as vaccination. The CAGR for the Asia Pacific region is estimated at 5.0%, indicating a growing recognition of the importance of vaccination in the context of public health. Meanwhile, Latin America and the Middle East & Africa are currently at nascent stages concerning Lyme disease vaccine awareness and availability, but there is potential for growth as public health initiatives evolve and awareness increases. Overall, the regional analysis highlights the varying levels of market maturity while emphasizing the global opportunity for Lyme disease vaccination initiatives.

Opportunities

The Lyme disease vaccine market presents numerous opportunities for growth, largely driven by increasing public awareness and the rising incidence of Lyme disease globally. As communities and health organizations become more educated about the risks associated with Lyme disease and the benefits of vaccination, there is significant potential for increased demand for vaccines. The expansion of digital health solutions and telemedicine can play a pivotal role in improving access to vaccination services, particularly in underserved regions. Additionally, partnerships between pharmaceutical companies and public health institutions can facilitate the development and distribution of new and innovative vaccine formulations. Ongoing research and development in vaccine technology also hold promise, as emerging methods and ingredients may lead to more effective vaccines that can provide better protection against Lyme disease.

Moreover, as climate change continues to impact tick populations and their geographical spread, it is anticipated that the demand for Lyme disease vaccines will rise in regions previously considered low risk. The establishment of targeted vaccination programs in high-risk areas presents an opportunity for public health initiatives to effectively combat the rising tide of tick-borne diseases. Furthermore, potential collaborations between governments, healthcare providers, and research institutions can enhance the overall infrastructure for Lyme disease prevention, leading to improved vaccination uptake and public health outcomes. By capitalizing on these opportunities, stakeholders in the Lyme disease vaccine market can work towards creating effective strategies for prevention and better health for communities worldwide.

Threats

Despite the promising outlook for the Lyme disease vaccine market, several threats could hinder its growth trajectory. One of the primary challenges is the public's perception of vaccine safety and efficacy, which can be influenced by misinformation and anti-vaccine sentiments. In recent years, vaccine hesitancy has emerged as a significant barrier to achieving high vaccination rates, especially in regions where Lyme disease is prevalent. This hesitancy can be exacerbated by concerns about potential side effects, which may lead to reduced demand for Lyme disease vaccines. Additionally, the complexity of vaccine development, particularly for Lyme disease due to the variability of its causative agents, presents scientific and regulatory challenges that could delay the introduction of new vaccines into the market.

Another potential restrainer for the Lyme disease vaccine market is the regulatory landscape surrounding vaccine approval and distribution. Stringent regulations and lengthy approval processes can slow down the introduction of innovative vaccine formulations, limiting the market's growth potential. Furthermore, financial constraints and disparities in healthcare access can impede the implementation of comprehensive vaccination programs in certain regions, particularly in low-income areas. To address these threats, stakeholders must prioritize public education and awareness campaigns to counter misinformation and build trust in vaccination. Collaborative efforts among healthcare providers, researchers, and policymakers are crucial in navigating the challenges posed by vaccine hesitancy and regulatory barriers, ensuring effective implementation of Lyme disease vaccination initiatives.

Competitor Outlook

• Valneva SE
• Pfizer Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Sanofi S.A.
• Novartis AG
• Inovio Pharmaceuticals, Inc.
• Seqirus
• Emergent BioSolutions Inc.
• Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals, Inc.
• MedImmune LLC
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Research Corporation Technologies, Inc.

The competitive landscape of the Lyme disease vaccine market is characterized by a mix of established pharmaceutical companies and emerging biotech firms. Major players such as Pfizer, GlaxoSmithKline, and Merck have made significant investments in research and development to advance their vaccine candidates against Lyme disease. These companies leverage their extensive experience, research capabilities, and distribution networks to effectively compete in the market. Additionally, collaborations and partnerships between pharmaceutical companies and research institutions are becoming increasingly common in the quest to develop innovative vaccine solutions. This collaborative approach allows for shared expertise, resources, and risk, fostering the advancement of novel vaccine technologies.

Emerging companies, such as Valneva and Inovio Pharmaceuticals, are also making strides in the Lyme disease vaccine market by developing cutting-edge vaccine candidates with unique formulations and delivery mechanisms. These companies are often at the forefront of scientific innovation, pushing the boundaries of vaccine technology to address gaps in existing prevention strategies. As the market evolves, these emerging players will likely play an essential role in shaping the future of Lyme disease vaccination, bringing fresh perspectives and novel solutions to a rapidly changing landscape.

As public health initiatives expand and the awareness of Lyme disease grows, the competitive dynamics of the Lyme disease vaccine market will continue to shift. Companies that adapt to changing market demands, invest in customer education, and collaborate effectively with stakeholders will be well-positioned for success. The importance of robust supply chains, effective marketing strategies, and ongoing research and development cannot be understated in this competitive landscape. With the continued evolution of vaccine technologies and the rising incidence of Lyme disease, the competitive outlook for this market remains promising.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Seqirus
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Valneva SE
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 MedImmune LLC
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca plc
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hoffmann-La Roche Ltd.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Emergent BioSolutions Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Inovio Pharmaceuticals, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Regeneron Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Takeda Pharmaceutical Company Limited
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Research Corporation Technologies, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Lyme Disease Vaccine Sales Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Retail Pharmacies
    • 6.1.4 E-Commerce
  • 6.2 Lyme Disease Vaccine Sales Market, By Product Type
    • 6.2.1 Recombinant Protein Vaccines
    • 6.2.2 Whole Cell Vaccines
    • 6.2.3 DNA Vaccines
    • 6.2.4 Live Attenuated Vaccines
    • 6.2.5 Subunit Vaccines
  • 6.3 Lyme Disease Vaccine Sales Market, By Ingredient Type
    • 6.3.1 Outer surface protein A (OspA)
    • 6.3.2 Outer surface protein C (OspC)
    • 6.3.3 VlsE
    • 6.3.4 DbpA
    • 6.3.5 DbpB
  • 6.4 Lyme Disease Vaccine Sales Market, By Distribution Channel
    • 6.4.1 Online Sales
    • 6.4.2 Retail Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Lyme Disease Vaccine Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Lyme Disease Vaccine Sales market is categorized based on

By Product Type

• Recombinant Protein Vaccines
• Whole Cell Vaccines
• DNA Vaccines
• Live Attenuated Vaccines
• Subunit Vaccines

By Application

• Hospitals
• Clinics
• Retail Pharmacies
• E-Commerce

By Distribution Channel

• Online Sales
• Retail Sales

By Ingredient Type

• Outer surface protein A (OspA)
• Outer surface protein C (OspC)
• VlsE
• DbpA
• DbpB

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Valneva SE
• Pfizer Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Sanofi S.A.
• Novartis AG
• Inovio Pharmaceuticals, Inc.
• Seqirus
• Emergent BioSolutions Inc.
• Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals, Inc.
• MedImmune LLC
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Research Corporation Technologies, Inc.